GlassScriptPhysician profile
Richard C Weiss
NPI 1013019918
$2,415.78
in general payments reported to CMS, 2019-2025
28 companies · $525 in 2025
The $525 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $145 · 2021: $320 · 2022: $280 · 2023: $174 · 2024: $293 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956 · Education: $36.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.74 |
| Education | $36.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $738.10 | 2019-2025 | |
| Janssen Biotech, INC. | $230.32 | 2021-2025 | Carvykti, Rybrevant, Darzalex |
| Astrazeneca Pharmaceuticals LP | $223.70 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $211.18 | 2019-2025 | Opdivo |
| Genentech USA, INC. | $141.15 | 2019-2025 | Phesgo, Perjeta, Kadcyla |
| Stemline Therapeutics INC. | $124.95 | 2024 | Orserdu |
| Merck Sharp & Dohme LLC | $103.55 | 2019-2020 | |
| Caris Mpi, INC. | $78.54 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $70.42 | 2020-2025 | Vyloy, Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $55.21 | 2021-2025 | Fruzaqla |
| Foundation Medicine, INC. | $44.68 | 2021 | |
| Amgen INC. | $43.83 | 2020-2023 | Lumakras |
| Daiichi Sankyo INC. | $41.13 | 2022 | |
| Janssen Scientific Affairs, LLC | $37.31 | 2025 | Rybrevant |
| Pfizer INC. | $29.83 | 2020-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $26.35 | 2021 | |
| Celgene Corporation | $25.96 | 2024 | Reblozyl |
| Eisai INC. | $23.81 | 2019 | |
| Geron Corporation | $23.22 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $18.72 | 2022 | |
| Incyte Corporation | $18.30 | 2019 | |
| Seagen INC. | $16.87 | 2023 | Adcetris |
| Lilly USA, LLC | $16.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.22 | 2019 | |
| G1 Therapeutics, INC. | $15.77 | 2022 | |
| Novo Nordisk INC | $14.59 | 2019 | |
| Glaxosmithkline, LLC. | $13.50 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.